Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mln-8054. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 6/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 4/20 | 1.00 |
| ▸ | PLK1 | P53350 | 4/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | HCK | P08631 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | FER | P16591 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 2/20 | 1.00 |
| ▸ | GRK5 | P34947 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mln-8054 SCHEMBL29372555 | 1.00 | AURKA (1.00) | AURKAAURKBPLK1GABRA1PLK4 | |
| Mln-8054 SCHEMBL29720492 | 1.00 | AURKA (1.00) | AURKAAURKBPLK1GABRA1PLK4 | |
| SCHEMBL2703627 | 0.96 | AURKA (0.92) | AURKAAURKBPLK1GABRA1PLK4 | |
| SCHEMBL2704004 | 0.95 | AURKA (0.90) | AURKAAURKBPLK1GABRA1PLK4 | |
| SCHEMBL2704677 | 0.94 | AURKA (0.89) | AURKAAURKBPLK1GABRA1PLK4 | |
| SCHEMBL2705306 | 0.93 | AURKA (0.87) | AURKAAURKBPLK1GABRA1PLK4 | |
| SCHEMBL2705316 | 0.93 | AURKA (0.86) | AURKAAURKBPLK1GABRA1PLK4 | |
| SCHEMBL2704222 | 0.92 | AURKA (0.85) | AURKAAURKBPLK1GABRA1PLK4 | |
| SCHEMBL2704262 | 0.92 | AURKA (0.85) | AURKAAURKBPLK1GABRA1PLK4 | |
| SCHEMBL2703250 | 0.92 | AURKA (1.00) | AURKAAURKBPLK1GABRA1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 845 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083906-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARM INC (US) | 2024-03-14 | — | — | US | claimed |
| WO-2022144780-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS | NATIONAL CANCER CENTER (JP) | 2022-07-07 | — | — | WO | claimed |
| US-11331272-B2 | Hyperstabilized liposomes increase targeting of mitotic cells | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2022-05-17 | — | — | US | claimed |
| EP-3400210-B1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | UNIV PARIS SACLAY (FR) | 2021-09-29 | — | — | EP | claimed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-05-25 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| WO-2019057920-A1 | BORONATE ESTER CROSSLINKED NANOGELS BASED ON MODIFIED POLYSACCHARIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-03-28 | — | — | WO | claimed |
| US-20110160228-A1 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION | CENTRE NATIONAL DE LA RECHERCHE SCIENRIFIQUE (CNRS) | 2011-06-30 | — | — | US | claimed |
| EP-2261226-A1 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-15 | — | — | EP | claimed |
| US-20100129471-A1 | ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERIZATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2010-05-27 | — | — | US | claimed |
| US-7572784-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | claimed |
| EP-1771450-B9 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE | MILLENNIUM PHARM INC (US) | 2008-12-24 | — | — | EP | claimed |
| EP-1905773-A2 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-02 | — | — | EP | claimed |
| EP-1771450-B1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE | MILLENNIUM PHARM INC (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1771450-A2 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2005111039-A2 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050256102-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256102-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885PLK1 4/4885 |
| US-20100129471-A1 | ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERIZATION | TUBB4A, TUBA4A, TUBB4B | AURKA 321/4885AURKB 335/4885PLK1 448/4885 |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | HDAC6, HDAC1, HDAC5 | AURKA 53/4885AURKB 52/4885PLK1 93/4885 |
| US-20240083906-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885PLK1 4/4885 |
| US-20110160228-A1 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION | TUBB4A, TUBA4A, TUBGCP4 | AURKA 322/4885AURKB 616/4885PLK1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.